TY - JOUR T1 - A Prospective Study Regarding the Efficacy and Safety of the BNT162b2 Vaccine in Patients With Solid Malignancies Undergoing Systemic Chemotherapy JF - In Vivo JO - In Vivo SP - 2780 LP - 2789 DO - 10.21873/invivo.13015 VL - 36 IS - 6 AU - EIKI YAMASAKI AU - FUKUTARO SHIMAMOTO AU - HIROKI NISHIKAWA AU - MASAHIRO GOTO AU - MITSUHIKO IWAMOTO AU - KOSEI KIMURA AU - AKIRA UKIMURA AU - NAOFUMI OOSAKA AU - KOHEI TANIGUCHI AU - FUMIHITO ONO AU - TETSUJI TERAZAWA AU - TOSHIFUMI YAMAGUCHI AU - KEN ASAISHI AU - TAKAKO IKEGAMI AU - KAZUHISA UCHIYAMA AU - SHIRO NAKAMURA AU - KAZUHIDE HIGUCHI Y1 - 2022/11/01 UR - http://iv.iiarjournals.org/content/36/6/2780.abstract N2 - Background/Aim: To prospectively evaluate the efficacy and safety of the BNT162b2 vaccine in solid cancer patients undergoing systemic chemotherapy (n=63). Patients and Methods: COVID-19 anti-spike protein antibody levels were measured before the first BNT162b2 vaccination, just before the second BNT162b2 vaccination, one month after the second BNT162b2 vaccination, and 3 months after the second BNT162b2 vaccination. Anti-spike protein antibody seropositivity was set at ≥0.8 U/ml. Results: Colorectal cancer was the most commonly observed primary disease (36.5%). ECOG-PS 0 was observed in the majority (52.4%) of patients. The overall response rate and the median (range) anti-spike protein antibody levels in the whole cohort at 3 months after the second BNT162b2 vaccination were 98.4% (62/63) and 206 (0.4-3,813) U/ml. None of the patients required postponement or discontinuation of systemic chemotherapy because of an adverse reaction. Conclusion: The BNT162b vaccine in solid cancer patients undergoing systemic chemotherapy is effective and safe. ER -